Nanjing Liwei Biomedical

Nanjing Liwei Biomedical is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the discovery and development of innovative small molecule drugs. The company focuses on challenging "undruggable" targets, particularly protein-protein interactions (PPIs), using its proprietary structure-based and fragment-based drug design platforms. Its lead candidate, LW-001, is a Menin-MLL inhibitor currently being evaluated in clinical trials for the treatment of acute leukemia. Beyond hematological malignancies, the company is advancing a pipeline of inhibitors targeting SHP2, SOS1, and USP1 for various solid tumors. Nanjing Liwei aims to provide precision medicine solutions for patients with high unmet medical needs in oncology.